Henk_final_edited_edited.png

Henk de Wilde

Chief Operating Officer and R&D Director

Henk is cofounder, COO and R & D Director of iQure Pharma Inc.  A pharmacist by training, Henk began his career as a Project Leader at Pharma Bio-Research B.V., (acquired by PRA in 2006), a Phase I Clinical Research Organization, where, in several senior management positions, he helped grow the company to be the largest Phase I unit in the world.  Henk then joined Roche as Project Leader for CNS and worked several years in Clinical Development, during which he set up and managed the procurement office for Clinical Operations, was responsible for all global outsourcing activities and later took over the management of all Project Leaders. From 1998 onwards, Henk was responsible for the clinical execution of Herceptin and was asked to create and head a cross-functional matrix unit dedicated to Oncology development and participated in multiple due diligence activities for new Oncology compounds.

After almost ten years in oncology, Henk turned his focus to Business Process Improvements and was responsible for the global implementation of a Clinical Trial Management System, a Trial Master File System, and a Safety Document Distribution System. In addition, he was involved in the development of two commercially available patient recruitment forecasting systems.

Since leaving Roche in 2017, Henk has been involved in the successful launch of three companies in venture capital, IT, and business process optimization for life science. In 2018 he joined Widler & Schiemann as Managing Director Europe supporting small and midsize pharma and biotech companies in their drug development of new medications.

  • Grey LinkedIn Icon